Table 1. Pre-OP Cut-Off-Levels (PDR & R15), Patient demographics, outcome- and laboratory parameters.
| Parameter | Collective (N = 137) | ||||||
|---|---|---|---|---|---|---|---|
| Pre OP | PDR ≥ 17%/min. | PDR < 17%/min. | P—value | R15 ≤ 8% | R15 > 8% | P—value | |
| N = / Median (Range/ %) | N = / Median (Range/ %) | N = / Median (Range/ %) | |||||
| Age | 63 (22–89) | 62 (22–84) | 69 (40–89) | 0.005 | 62 (22–89) | 67 (40–86) | 0.12 |
| Sex | |||||||
| Male | 88 (64.2%) | 67 (63.8%) | 21 (65.6%) | 0.85 | 69 (63.3%) | 19 (67.9%) | 0.65 |
| Female | 49 (35.8%) | 38 (36.2%) | 11 (34.4%) | 40 (36.7%) | 9 (32.1%) | ||
| Neoplastic entity | |||||||
| mCRC | 59 (43.1%) | 43 (41.0%) | 16 (50%) | 0.05 | 42 (38.5%) | 17 (60.7%) | 0.10 |
| HCC | 30 (21.9%) | 19 (18.1%) | 11 (34.4%) | 23 (21.1%) | 7 (25.0%) | ||
| CCC | 23 (16.8%) | 19 (18.1%) | 4 (12.5%) | 20 (18.3%) | 3 (10.7%) | ||
| Non neoplastic Adenomas or Haemangiomas | 13 (9.5%) | 13 (12.4%) | 0 (0,0%) | 13 (11.9%) | 0 (0.0%) | ||
| Others | 12 (8.8%) | 11 (10.5%) | 1 (3.1%) | 11 (10.1%) | 1 (3.6%) | ||
| Postoperative CTx | |||||||
| yes | 51 (37.2%) | 40 (38.1%) | 11 (34.4%) | 0.792 | 40 (36.7%) | 11 (39.3%) | 0.70 |
| Hepatic resection | |||||||
| Major | 60 (43.8%) | 46 (76.7%) | 14 (43.8%) | 0.10 | 50 (45.9%) | 10 (35.7%) | 0.33 |
| Minor | 77 (56.2%) | 59 (56.2%) | 18 (56.3%) | 59 (54.1%) | 18 (64.3%) | ||
| LD | |||||||
| yes | 11 (8%) | 5 (4.8%) | 6 (18.8%) | 0.011 | 6 (5.5%) | 5 (17.9%) | 0.032 |
| Child Pugh Score/ Missing values (N = 19) | |||||||
| A | 109 (92.4%) | 83 (93.3%) | 26 (89.7%) | 0.53 | 86 (93.5%) | 23 (88.5%) | 0.40 |
| B | 9 (7.6%) | 6 (6.7%) | 3 (10.3%) | 6 (6.5%) | 3 (11.5%) | ||
| MELD Score | 6 (6–16) | 6 (6–16) | 7 (6–15) | 0.014 | 6 (6–16) | 7 (6–15) | 0.047 |
| Preoperative parameters | |||||||
| PDR%/min. | 22.1 (7.6–42.8) | 24.0 (17.3–42.8) | 15.9 (7.6–17.0) | 24.0 (16.0–42.8) | 15.30 (7.6–29.5) | ||
| R15% | 3.6 (0.0–32.0) | 2.5 (0.0–9.1) | 9.2 (1.2–32.0) | 2.6 (0.0–8.0) | 9.80 (8.2–32.0) | ||
| SB mg/dl | 0.6 (0.2–6.6) | 0.6 (0.3–2.8) | 0.7 (0.2–6.6) | 0.41 | 0.6 (0.3–3.2) | 0.6 (0.2–6.6) | 0.85 |
| PT% a | 102 (0–150) | 103 (0–147) | 89 (40–150) | 0.65 | 103 (0–147) | 101 (40–150) | 0.79 |
| ALP U/l | 86.0(14.0–946.0) | 84.5 (14.0–946.0) | 92.5 (43.0–396.0) | 0.47 | 85.0 (14.0–946.0) | 91.0 (43.0–418.0) | 0.51 |
| GGT U/l | 58.0 (11.0–699.0) | 58.0 (11.0–670.0) | 59.5 (18.0–699.0) | 0.21 | 54.0 (11.0–670.0) | 73.0 (19.0–699.0) | 0.10 |
| AST U/l | 29 (14–208) | 28 (14–113) | 33 (18–208) | 0.08 | 28 (14–946) | 32 (18–208) | 0.12 |
| ALT U/l | 26.0 (6.0–196.0) | 27.0 (6.0–167.0) | 25.5 (13.0–196.0) | 0.34 | 26.0 (6.0–196.0) | 27.5 (17.0–120.0) | 0.15 |
| Albumin g/l | 42.2 (32.5–52.4) | 42.5 (33.1–52.4) | 41.0 (32.5–46.9) | 0.037 | 42.4 (33.1–52.4) | 41.0 (32.5–46.9) | 0.038 |
| Platelets (x10^3/μl) | 226.5 (92.0–492.0) | 236.0 (92.0–492.0) | 213.0 (103.0–378.0) | 0.033 | 236.0 (92.0–492.0) | 207.5 (132.0–431.0) | 0.036 |
| Creatinine mg/dl | 0.9 (0.5–1.9) | 0.8 (0.5–1.9) | 0.9 (0.6–1.8) | 0.49 | 0.9 (0.5–1.9) | 0.8 (0.6–1.8) | 0.13 |
| INR | 0.9 (0.7–1.8) | 0.9 (0.7–1.6) | 1.0 (0.7–1.8) | 0.39 | 0.9 (0.7–1.6) | 1.0 (0.7–1.8) | 0.89 |
ALP, alkaline phosphatase; ALT, alanine amino transferase; AST, aspartate amino transferase; CCC, cholangiocellular carcinoma; CTx, chemo therapy; GGT, gamma glutamyl transferase; HCC, hepatocellular carcinoma; INR, international normalized ratio; LD, liver dysfunction; mCRC, metastatic colorectal cancer; MELD, model of end-stage liver diseases, PDR, plasma diffusion rate; pre OP, preoperative; PT, prothrombin time; R15, retention rate at 15 minutes; SB, serum bilirubin
a PT is expressed in relation to the coagulation time of a healthy person (i.e. Quick). Accordingly, it is illustrated in percentage.